Absci (NASDAQ:ABSI – Get Free Report) and Opus Genetics (NASDAQ:IRD – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.
Profitability
This table compares Absci and Opus Genetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Absci | -7,756.38% | -61.71% | -54.52% |
| Opus Genetics | -1,091.82% | -338.88% | -150.13% |
Earnings & Valuation
This table compares Absci and Opus Genetics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Absci | $2.80 million | 540.57 | -$115.18 million | ($0.80) | -11.03 |
| Opus Genetics | $14.20 million | 27.18 | -$49.59 million | ($1.35) | -3.46 |
Opus Genetics has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
52.0% of Absci shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 10.5% of Absci shares are owned by company insiders. Comparatively, 11.7% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Absci and Opus Genetics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Absci | 1 | 0 | 8 | 0 | 2.78 |
| Opus Genetics | 1 | 1 | 15 | 1 | 2.89 |
Absci currently has a consensus target price of $13.43, indicating a potential upside of 52.25%. Opus Genetics has a consensus target price of $10.69, indicating a potential upside of 128.96%. Given Opus Genetics’ stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than Absci.
Risk and Volatility
Absci has a beta of 2.42, suggesting that its share price is 142% more volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.
Summary
Opus Genetics beats Absci on 9 of the 15 factors compared between the two stocks.
About Absci
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.
About Opus Genetics
Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.
